EU – Baltic States, Investments, Markets and Companies, Medicine

Herantis Pharma Plc is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson’s disease, and secondary lymphedema, informs NASDAQ OMX Nordic.

Pekka Simula, CEO of Herantis Pharma Plc, commented: ”The First North listing was an optimal way to raise funding for our product pipeline. It’s been 14 years since the last IPO of a drug development company in Finland – we hope that our success encourages others to follow.”

Lauri Rosendahl, President of NASDAQ OMX Helsinki, said: “We welcome Herantis Pharma Plc to First North and to our Health Care sector. Herantis Pharma Plc is a great example of an innovative growth company that is utilizing our First North platform to achieve increased investor exposure and awareness. We look forward to a long-standing partnership with the company and its shareholders.”

Herantis Pharma Plc has appointed UB Capital Oy as Certified Adviser.

First North is regulated as a multilateral trading facility, operated by the different exchanges within NASDAQ OMX Nordic. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.